MedPath

BILL & MELINDA GATES FOUNDATION

BILL & MELINDA GATES FOUNDATION logo
🇪🇹Ethiopia
Ownership
Private
Established
1997-01-01
Employees
1K
Market Cap
-
Website
http://www.gatesfoundation.org

Clinical Trials

18

Active:4
Completed:5

Trial Phases

2 Phases

Phase 1:1
Not Applicable:10

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Not Applicable
10 (90.9%)
Phase 1
1 (9.1%)
No trials found

News

Centivax Secures $45 Million Series A to Advance Universal Flu Vaccine into Phase I Clinical Trial

Centivax raised an oversubscribed $45 million Series A round led by Future Ventures to advance its universal flu vaccine through Phase I clinical trials beginning within eight months.

Deerfield Management Raises Over $600M for Third Biotech Innovation Fund

• Deerfield Management has secured more than $600 million for its third innovation fund, focusing on investments in drugs, medical devices, and healthcare services. • The new fund will operate from Deerfield's "Cure" campus in New York City and leverage partnerships with nearly 30 academic institutions to nurture healthcare startups. • With over $15 billion in assets under management, Deerfield's investment strategy comes amid a shift in biotech venture funding toward larger, more selective "megarounds" exceeding $100 million.

Dyadic International Reports Strong 2024 Performance with $1.9 Million in Milestone and License Revenue

Dyadic International reported $3.5 million in total revenue for 2024, including approximately $1.9 million in milestone and license revenue, demonstrating significant progress in commercializing its proprietary protein production platforms.

Micron Biomedical Advances Needle-Free Vaccine Technology with $43 Million in Funding

Micron Biomedical has secured $43 million in total grant funding, including a recent $7.5 million grant from the Bill & Melinda Gates Foundation to support measles-rubella vaccine development and manufacturing scale-up.

Insud Pharma and Gates Foundation Partner to Develop Sublingual Oxytocin for Postpartum Hemorrhage Prevention

Insud Pharma receives $2.7 million from the Bill & Melinda Gates Foundation to advance a sublingual oxytocin formulation for preventing postpartum hemorrhage (PPH).

Late-Stage Trials Offer Hope in the Fight Against Tuberculosis with Novel Vaccine Candidates

Six tuberculosis vaccine candidates are currently undergoing Phase 3 clinical trials, marking a crucial step towards combating the disease and antimicrobial resistance.

HIV Vaccine Breakthrough: New Candidate Successfully Generates Broadly Neutralizing Antibodies

NIAID-supported clinical trial demonstrates that an HIV vaccine candidate can elicit broadly neutralizing antibodies (bNAbs) targeting the membrane proximal external region (MPER) of HIV, a crucial step toward developing an effective preventive vaccine.

Evotec Receives $2.5M Gates Foundation Grant for iPSC-Based Teratogenicity Platform

Evotec has joined the Bill & Melinda Gates Foundation's Global Health Discovery Collaboratory (GHDC) after receiving a $2.5 million grant to support its innovative iPSC-derived teratogenicity platform.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.